ESSA Pharma (EPIX) Stock Price, News & Analysis

Company Overview

ESSA Pharma Inc. is a clinical‐stage pharmaceutical company dedicated to developing novel therapies for prostate cancer. The company’s proprietary approach targets the androgen receptor (AR) via its N-terminal domain, a strategy designed to overcome resistance mechanisms that limit current hormone therapies. ESSA’s lead candidate leverages this unique mechanism to address castration‐resistant prostate cancer, positioning the company at the forefront of AR-focused drug discovery.

Central to ESSA’s pipeline is its second‐generation AR N-terminal domain inhibitor, which builds on the proof-of-concept established by the company’s first‐generation program. This investigational therapy is engineered to bind a site on the AR that is not addressed by existing treatments, offering potential benefits for patients who have progressed on standard therapies. Ongoing clinical studies are evaluating safety, tolerability and initial efficacy signals in men with advanced prostate cancer.

Founded in 2014 and headquartered in Vancouver, Canada, ESSA Pharma also maintains research facilities in the United States to support its global clinical development efforts. The company collaborates with academic institutions and clinical partners across North America and Europe, enrolling patients at leading cancer centers. These partnerships enable ESSA to accelerate trial timelines and broaden access to its investigational agents.

ESSA Pharma is led by President and Chief Executive Officer Kelly Martin, Ph.D., whose background spans oncology drug development and strategic biopharmaceutical leadership. The executive team includes seasoned professionals in clinical operations, regulatory affairs and commercial planning, supported by a scientific advisory board composed of experts in prostate cancer biology and translational research.

Key Stats

• Today's Range: $1.86 to $1.87
• 50-Day Range: $1.61 to $1.87
• 52-Week Range: $1.40 to $7.88
• Volume: 641,094 shs
• Average Volume: 359,394 shs
• Market Capitalization: $82.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Hold

ESSA Pharma Stock Analysis - MarketRank™

ESSA Pharma scored higher than 21% of companies evaluated by MarketBeat, and ranked 846th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

ESSA Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

ESSA Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ESSA Pharma are expected to grow in the coming year, from ($0.42) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ESSA Pharma is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ESSA Pharma is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ESSA Pharma has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.99% of the float of ESSA Pharma has been sold short.

Short Interest Ratio / Days to Cover

ESSA Pharma has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in ESSA Pharma has recently increased by 4.02%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ESSA Pharma does not currently pay a dividend.

Dividend Growth

ESSA Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.99% of the float of ESSA Pharma has been sold short.

Short Interest Ratio / Days to Cover

ESSA Pharma has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in ESSA Pharma has recently increased by 4.02%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.89

News Sentiment

ESSA Pharma has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for ESSA Pharma this week, compared to 4 articles on an average week.

Search Interest

1 people have searched for EPIX on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ESSA Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.50% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EPIX Stock Analysis - Frequently Asked Questions

How have EPIX shares performed this year?

ESSA Pharma's stock was trading at $1.79 on January 1st, 2025. Since then, EPIX stock has increased by 3.9% and is now trading at $1.86.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05.

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Jabil (JBL), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EPIX
• CIK: 1633932
• Web: www.essapharma.com
• Phone: 778-331-0962
• Fax: 604-738-4080
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ESSA Pharma: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: +7.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -23.48%
• Return on Assets: -22.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 67.15
• Quick Ratio: 67.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.81 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 44,389,000
• Free Float: 37,509,000
• Market Cap: $82.56 million
• Optionable: Optionable
• Beta: 1.56